Cargando…

Minimal residual disease in multiple myeloma: are we there yet?

Detalles Bibliográficos
Autores principales:	Devarakonda, Srinivas, Jethava, Yogesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689536/ https://www.ncbi.nlm.nih.gov/pubmed/33294170 http://dx.doi.org/10.2217/ijh-2020-0018

Ejemplares similares

Newborn screening for neurodevelopmental diseases: Are we there yet?
por: Chung, Wendy K., et al.
Publicado: (2022)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Urgent start peritoneal dialysis: are we there yet?
por: Greenberg, Keiko I., et al.
Publicado: (2020)

Automatic detection of rib fractures: Are we there yet?
por: Blum, A, et al.
Publicado: (2020)

Are we there yet? An update on transitional care in rheumatology
por: McDonagh, Janet E., et al.
Publicado: (2018)

β-blockers in septic shock: are we there yet?
por: Cruz, Madalena Coutinho, et al.
Publicado: (2017)

Early detection of central lung cancer: are we there yet?
por: Musani, Ali I, et al.
Publicado: (2015)

Screening for type 1 diabetes: are we nearly there yet?
por: Narendran, Parth
Publicado: (2018)

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
por: Zátopková, Martina, et al.
Publicado: (2022)

Role of Stem Cell Transplantation in Multiple Myeloma
por: Devarakonda, Srinivas, et al.
Publicado: (2021)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Modulation of macrophage polarity for treatment of acute pancreatitis: Are we there yet?
por: Sahay, Preeti, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
por: Zamagni, Elena, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New
por: Bravo-Pérez, Carlos, et al.
Publicado: (2021)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Patient and Public Engagement in Integrated Knowledge Translation Research: Are we there yet?
por: Banner, Davina, et al.
Publicado: (2019)

Commentary: Fibrin glue in rhegmatogenous retinal detachment repair—Are we there yet?
por: Anshuman, Kumar, et al.
Publicado: (2019)

Commentary: Prognostication of uveal melanoma based on molecular diagnosis - Are we there yet?
por: Attiku, Yamini, et al.
Publicado: (2019)

Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine—Are We There Yet?
por: Lourenço, Diana, et al.
Publicado: (2022)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum
por: Tapia-Alveal, Claudia, et al.
Publicado: (2020)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium
por: Krzywdzińska, Agnieszka, et al.
Publicado: (2021)

Coexisting multiple myeloma, lymphoma, and non-small cell lung cancer: a case report and review of the literature
por: Khade, Parth, et al.
Publicado: (2017)

Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2005)

Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination
por: Alexander, Neal D. E.
Publicado: (2015)

Video-assisted laryngoscopic devices: Have we found the panacea for difficult airway yet?
por: Gupta, Anju
Publicado: (2017)

Commentary: Coronavirus disease 2019 in cardiac surgery: We are still learning and have yet to see all possible complications
por: Ramzy, Danny
Publicado: (2020)

Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
por: Bertuglia, Giuseppe, et al.
Publicado: (2022)

Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma
por: Zhan, Xin, et al.
Publicado: (2017)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fjgrk8j4mrea2t09g7umtj5kqs